The purpose of this study is to determine the safety and efficacy of intrathecal treatment
delivered to the cerebrospinal fluid (CSF) of mesenchymal stem cells in ALS patients every 3
months for a total of 4 injections over 12 months.
Mesenchymal stem cells (MSCs) are a type of stem cell that can be grown into a number of
different kinds of cells. In this study, MSCs will be taken from the subject's body fat and
grown. CSF is the fluid surrounding the spine.
The use of mesenchymal stem cells is considered investigational, which means it has not been
approved by the Food and Drug Administration (FDA) for routine clinical use. However, the FDA
has allowed the use of mesenchymal stem cells in this research study.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
State of Minnesota Regenerative Medicine Minnesota